Formoterol treatment down-regulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

Busquets,Sílvia; Toledo,Míriam; Marmonti,Enrica; Orpí,Marcel; Capdevila,Eva; Betancourt,Angelica; López-Soriano,Francisco  J.; Argilés,Josep  M.

doi:10.3892/ol.2011.442

Formoterol treatment down-regulates the myostatin system in skeletal muscle of cachectic tumour-bearing rats

Authors:
- Sílvia Busquets
- Míriam Toledo
- Enrica Marmonti
- Marcel Orpí
- Eva Capdevila
- Angelica Betancourt
- Francisco J. López-Soriano
- Josep M. Argilés
View Affiliations

Affiliations: Cancer Research Group, Departament de Bioquímica i Biologia Molecular, Facultat de Biologia, Universitat de Barcelona, 08028 Barcelona, Spain
Published online on: October 13, 2011 https://doi.org/10.3892/ol.2011.442
Pages: 185-189

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Cachexia is a common systemic manifestation. Additionally, myostatin is known to be a negative regulator of skeletal muscle development. The present study aimed to investigate whether formoterol down-regulates the myostatin system in skeletal muscle of tumour-bearing rats. Real-time PCR and Western blotting were used for the analysis. Results showed that rats bearing the Yoshida AH-130 ascites hepatoma, a cachexia-inducing tumour, exhibited marked muscle wasting that affected the mass of the muscles studied. The cachectic animals exhibited a significant increase in the mRNA levels of the myostatin receptor (ActIIB) in gastrocnemius muscles. Notably, the expression of the various forms of follistatin, a protein with the opposite effects to those of myostatin, was significantly reduced as a result of the implantation of the tumour. When the animals were treated with formoterol, a β-agonist with anti-cachectic potential, increases in skeletal muscle weights were observed. The β-agonist significantly increased levels of various follistatin isoforms and significantly decreased the expression levels of the myostatin receptor. In addition, formoterol treatment resulted in a significant decrease of the myostatin protein content of the gastrocnemius muscle. In conclusion, the results presented indicate that certain anabolic actions of formoterol on the skeletal muscle of cachectic animals may be mediated via the myostatin system.

View Figures

View References

1	Harvey KB, Bothe A Jr and Blackburn GL: Nutritional assessment and patient outcome during oncological therapy. Cancer. 43:2065–2069. 1979. View Article : Google Scholar : PubMed/NCBI
2	Argiles JM, Alvarez B and Lopez-Soriano FJ: The metabolic basis of cancer cachexia. Med Res Rev. 17:477–498. 1997. View Article : Google Scholar : PubMed/NCBI
3	Argiles JM and Lopez-Soriano FJ: The ubiquitin-dependent proteolytic pathway in skeletal muscle: its role in pathological states. Trends Pharmacol Sci. 17:223–226. 1996. View Article : Google Scholar : PubMed/NCBI
4	Sanchis D, Busquets S, Alvarez B, Ricquier D, Lopez-Soriano FJ and Argiles JM: Skeletal muscle UCP2 and UCP3 gene expression in a rat cancer cachexia model. FEBS Lett. 436:415–418. 1998. View Article : Google Scholar : PubMed/NCBI
5	Van Royen M, Carbo N, Busquets S, et al: DNA fragmentation occurs in skeletal muscle during tumor growth: A link with cancer cachexia? Biochem Biophys Res Commun. 270:533–537. 2000.PubMed/NCBI
6	Lee SJ and McPherron AC: Myostatin and the control of skeletal muscle mass. Curr Opin Genet Dev. 9:604–607. 1999. View Article : Google Scholar : PubMed/NCBI
7	Sharma M, Langley B, Bass J and Kambadur R: Myostatin in muscle growth and repair. Exerc Sport Sci Rev. 29:155–158. 2001. View Article : Google Scholar : PubMed/NCBI
8	Tsuchida K: Targeting myostatin for therapies against muscle-wasting disorders. Curr Opin Drug Discov Devel. 11:487–494. 2008.PubMed/NCBI
9	McPherron AC, Lawler AM and Lee SJ: Regulation of skeletal muscle mass in mice by a new TGF-beta superfamily member. Nature. 387:83–90. 1997. View Article : Google Scholar : PubMed/NCBI
10	Elkasrawy MN and Hamrick MW: Myostatin (GDF-8) as a key factor linking muscle mass and bone structure. J Musculoskelet Neuronal Interact. 10:56–63. 2010.PubMed/NCBI
11	Lee SJ: Sprinting without myostatin: a genetic determinant of athletic prowess. Trends Genet. 23:475–477. 2007. View Article : Google Scholar : PubMed/NCBI
12	Lee SJ: Regulation of muscle mass by myostatin. Annu Rev Cell Dev Biol. 20:61–86. 2004. View Article : Google Scholar : PubMed/NCBI
13	Anderson SB, Goldberg AL and Whitman M: Identification of a novel pool of extracellular pro-myostatin in skeletal muscle. J Biol Chem. 283:7027–7035. 2008. View Article : Google Scholar : PubMed/NCBI
14	Hill JJ, Davies MV, Pearson AA, et al: The myostatin propeptide and the follistatin-related gene are inhibitory binding proteins of myostatin in normal serum. J Biol Chem. 277:40735–40741. 2002. View Article : Google Scholar : PubMed/NCBI
15	Guo T, Jou W, Chanturiya T, Portas J, Gavrilova O and McPherron AC: Myostatin inhibition in muscle, but not adipose tissue, decreases fat mass and improves insulin sensitivity. PLoS One. 4:e49372009. View Article : Google Scholar : PubMed/NCBI
16	Wolfman NM, McPherron AC, Pappano WN, et al: Activation of latent myostatin by the BMP-1/tolloid family of metalloproteinases. Proc Natl Acad Sci USA. 100:15842–15846. 2003. View Article : Google Scholar : PubMed/NCBI
17	Lee SJ: Genetic analysis of the role of proteolysis in the activation of latent myostatin. PLoS One. 3:e16282008. View Article : Google Scholar : PubMed/NCBI
18	De Caestecker M: The transforming growth factor-beta superfamily of receptors. Cytokine Growth Factor Rev. 15:1–11. 2004.
19	Rodino-Klapac LR, Haidet AM, Kota J, Handy C, Kaspar BK and Mendell JR: Inhibition of myostatin with emphasis on follistatin as a therapy for muscle disease. Muscle Nerve. 39:283–296. 2009. View Article : Google Scholar : PubMed/NCBI
20	Allendorph GP, Vale WW and Choe S: Structure of the ternary signaling complex of a TGF-beta superfamily member. Proc Natl Acad Sci USA. 103:7643–7648. 2006. View Article : Google Scholar : PubMed/NCBI
21	Steelman CA, Recknor JC, Nettleton D and Reecy JM: Transcriptional profiling of myostatin-knockout mice implicates Wnt signaling in postnatal skeletal muscle growth and hypertrophy. FASEB J. 20:580–582. 2006.PubMed/NCBI
22	Joulia-Ekaza D and Cabello G: The myostatin gene: physiology and pharmacological relevance. Curr Opin Pharmacol. 7:310–315. 2007. View Article : Google Scholar
23	Whittemore LA, Song K, Li X, et al: Inhibition of myostatin in adult mice increases skeletal muscle mass and strength. Biochem Biophys Res Commun. 300:965–971. 2003. View Article : Google Scholar : PubMed/NCBI
24	Durieux AC, Amirouche A, Banzet S, et al: Ectopic expression of myostatin induces atrophy of adult skeletal muscle by decreasing muscle gene expression. Endocrinology. 148:3140–3147. 2007. View Article : Google Scholar : PubMed/NCBI
25	McFarlane C, Plummer E, Thomas M, et al: Myostatin induces cachexia by activating the ubiquitin proteolytic system through an NF-κB-independent, FoxO1-dependent mechanism. J Cell Physiol. 209:501–514. 2006.PubMed/NCBI
26	Stock MJ and Rothwell NJ: Effects of β-adrenergic agonists on metabolism and body composition. Control and manipulation of Animal Growth. Buttery PJ, Hayes NB and Lindsay DB: Butterworths; London: pp. 249–257. 1985
27	Kim YS and Sainz RD: Beta-adrenergic agonists and hypertrophy of skeletal muscles. Life Sci. 50:397–407. 1992. View Article : Google Scholar : PubMed/NCBI
28	Agbenyega ET and Wareham AC: Effect of clenbuterol on skeletal muscle atrophy in mice induced by the glucocorticoid dexamethasone. Comp Biochem Physiol Comp Physiol. 102:141–145. 1992. View Article : Google Scholar : PubMed/NCBI
29	Rajab P, Fox J, Riaz S, Tomlinson D, Ball D and Greenhaff PL: Skeletal muscle myosin heavy chain isoforms and energy metabolism after clenbuterol treatment in the rat. Am J Physiol Regul Integr Comp Physiol. 279:R1076–R1081. 2000.PubMed/NCBI
30	Hinkle RT, Hodge KM, Cody DB, Sheldon RJ, Kobilka BK and Isfort RJ: Skeletal muscle hypertrophy and anti-atrophy effects of clenbuterol are mediated by the beta2-adrenergic receptor. Muscle Nerve. 25:729–734. 2002. View Article : Google Scholar : PubMed/NCBI
31	Wineski LE, von Deutsch DA, Abukhalaf IK, Pitts SA, Potter DE and Paulsen DF: Muscle-specific effects of hindlimb suspension and clenbuterol in mature male rats. Cells Tissues Organs. 171:188–198. 2002. View Article : Google Scholar : PubMed/NCBI
32	Busquets S, Figueras MT, Fuster G, et al: Anticachectic effects of formoterol: a drug for potential treatment of muscle wasting. Cancer Res. 64:6725–6731. 2004. View Article : Google Scholar : PubMed/NCBI
33	Tessitore L, Costelli P, Bonetti G and Baccino FM: Cancer cachexia, malnutrition, and tissue protein turnover in experimental animals. Arch Biochem Biophys. 306:52–58. 1993. View Article : Google Scholar : PubMed/NCBI
34	Chomczynski P and Sacchi N: Single-step method of RNA isolation by acid guanidinium thiocyanate-phenol-chloroform extraction. Anal Biochem. 162:156–159. 1987. View Article : Google Scholar : PubMed/NCBI
35	Gonzalez-Cadavid NF, Taylor WE, Yarasheski K, et al: Organization of the human myostatin gene and expression in healthy men and HIV-infected men with muscle wasting. Proc Natl Acad Sci USA. 95:14938–14943. 1998. View Article : Google Scholar : PubMed/NCBI
36	Costelli P, Muscaritoli M, Bonetto A, et al: Muscle myostatin signalling is enhanced in experimental cancer cachexia. Eur J Clin Invest. 38:531–538. 2008. View Article : Google Scholar : PubMed/NCBI
37	Joulia-Ekaza D and Cabello G: Myostatin regulation of muscle development: molecular basis, natural mutations, physiopathological aspects. Exp Cell Res. 312:2401–2414. 2006. View Article : Google Scholar
38	Kollias HD and McDermott JC: Transforming growth factor-beta and myostatin signaling in skeletal muscle. J Appl Physiol. 104:579–587. 2008. View Article : Google Scholar : PubMed/NCBI
39	Shimasaki S, Koga M, Esch F, et al: Primary structure of the human follistatin precursor and its genomic organization. Proc Natl Acad Sci USA. 85:4218–4222. 1988. View Article : Google Scholar : PubMed/NCBI
40	Aoki MS, Soares AG, Miyabara EH, Baptista IL and Moriscot AS: Expression of genes related to myostatin signaling during rat skeletal muscle longitudinal growth. Muscle Nerve. 40:992–999. 2009. View Article : Google Scholar : PubMed/NCBI
41	Ouchi N, Oshima Y, Ohashi K, et al: Follistatin-like 1, a secreted muscle protein, promotes endothelial cell function and revascularization in ischemic tissue through a nitric-oxide synthase-dependent mechanism. J Biol Chem. 283:32802–32811. 2008. View Article : Google Scholar
42	Cowling BS, McGrath MJ, Nguyen MA, et al: Identification of FHL1 as a regulator of skeletal muscle mass: implications for human myopathy. J Cell Biol. 183:1033–1048. 2008. View Article : Google Scholar : PubMed/NCBI
43	Zamora E, Lupon J, Simo R and Galan A: Myostatin serum levels in heart failure. Eur J Heart Fail. 12:1379author reply 1379–1380. 2010. View Article : Google Scholar : PubMed/NCBI
44	Llovera M, Carbo N, Lopez-Soriano J, et al: Different cytokines modulate ubiquitin gene expression in rat skeletal muscle. Cancer Lett. 133:83–87. 1998. View Article : Google Scholar : PubMed/NCBI
45	Llovera M, Garcia-Martinez C, Agell N, et al: Ubiquitin and proteasome gene expression is increased in skeletal muscle of slim AIDS patients. Int J Mol Med. 2:69–73. 1998.PubMed/NCBI
46	Llovera M, Garcia-Martinez C, Lopez-Soriano J, et al: Role of TNF receptor 1 in protein turnover during cancer cachexia using gene knockout mice. Mol Cell Endocrinol. 142:183–189. 1998. View Article : Google Scholar : PubMed/NCBI
47	Llovera M, Garcia-Martinez C, Agell N, Lopez-Soriano FJ and Argiles JM: Muscle wasting associated with cancer cachexia is linked to an important activation of the ATP-dependent ubiquitin-mediated proteolysis. Int J Cancer. 61:138–141. 1995. View Article : Google Scholar : PubMed/NCBI
48	Garcia-Martinez C, Llovera M, Agell N, Lopez-Soriano FJ and Argiles JM: Ubiquitin gene expression in skeletal muscle is increased by tumour necrosis factor-alpha. Biochem Biophys Res Commun. 201:682–686. 1994. View Article : Google Scholar : PubMed/NCBI
49	Llovera M, Garcia-Martinez C, Agell N, Marzabal M, Lopez-Soriano FJ and Argiles JM: Ubiquitin gene expression is increased in skeletal muscle of tumour-bearing rats. FEBS Lett. 338:311–318. 1994. View Article : Google Scholar : PubMed/NCBI
50	Schneyer A, Tortoriello D, Sidis Y, Keutmann H, Matsuzaki T and Holmes W: Follistatin-related protein (FSRP): a new member of the follistatin gene family. Mol Cell Endocrinol. 180:33–38. 2001. View Article : Google Scholar : PubMed/NCBI